By Frank Prenesti
Date: Tuesday 19 Mar 2024
LONDON (ShareCast) - (Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.
Fusion specialises in radioconjugates, which combine the precise targeting of antibodies, small molecules or peptides with potent medical radioisotopes to deliver radiation directly to cancer cells.
AstraZeneca will pay $21 a share for Fusion, a premium of more than 97% to the US-listed company's closing price on Monday and a non-transferable contingent value right of $3 per share, taking the combined transaction value to about $2.4bn.
Reporting by Frank Prenesti for Sharecast.com
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 12,024.00p |
Change Today | 36.00p |
% Change | 0.30 % |
52 Week High | 12,488.00 |
52 Week Low | 9,501.00 |
Volume | 3,697,512 |
Shares Issued | 1,550.22m |
Market Cap | £186,399m |
RiskGrade | 123 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 8 |
Buy | 15 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 1 |
Total | 29 |
Latest | Previous | |
---|---|---|
2nd Interim | 1st Interim | |
Ex-Div | 22-Feb-24 | 10-Aug-23 |
Paid | 25-Mar-24 | 11-Sep-23 |
Amount | 197.00¢ | 93.00¢ |
Time | Volume / Share Price |
09:00 | 500 @ 12,086.00p |
09:23 | 500 @ 12,080.00p |
16:17 | 0 @ 12,030.00p |
16:20 | 0 @ 12,028.00p |
16:16 | 0 @ 12,022.00p |
You are here: research